VRDN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Viridian Therapeutics Inc (VRDN) is not a strong buy for a beginner investor with a long-term strategy at this moment. The technical indicators show a bearish trend, and the stock has experienced a significant post-market price drop. While analysts maintain positive ratings with reduced price targets, there are no immediate catalysts or strong trading signals to justify a buy. The options data reflects a low put-call ratio, indicating bullish sentiment, but this is insufficient to override the overall negative momentum.
The MACD is positive and expanding, suggesting mild bullish momentum. However, the RSI is neutral, and the moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading below its pivot level of 16.37, with key support at 15.629 and resistance at 17.111.
Analysts maintain Outperform and Buy ratings despite reduced price targets. RBC Capital highlighted strong Q1 results for Viridian's subcutaneous program, which demonstrated better-than-expected performance.
The stock has faced significant price target reductions from multiple analysts due to competitive pressures from Amgen's Tepezza. The bearish moving averages and a 4.99% post-market price drop further indicate negative sentiment. No recent news or Congress trading data is available to provide additional support.
No financial data is available for analysis.
Analysts maintain positive ratings (Outperform and Buy), but price targets have been reduced across the board, with the latest target ranging from $24 to $39.
